Several publications demonstrate the association of CD44 with poor prognosis in EOC patients (37, 39–42), including a recent systematic meta-analysis of 18 studies consisting of more than 2000 ovarian cancer patients, which showed a significant correlation between CD44 expression and poor 5-year overall survival (43). The gene discussed is CD44; the disease is ovarian cancer.